Submit

Login Login

Register Register

Home / Journals / OR / Special Issue / New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle
Journal Menu
Special Issues
Table of Content

All issues

Online First

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle

Submission Deadline: 30 June 2025 (closed) View: 3513 Submit to Journal

Guest Editors

Dr. Chen Li, Department of Biology, Chemistry, Pharmacy, Free University of Berlin, Germany. E-mail:chen.li.scholar@gmail.com; chen.li@fu-berlin.de

Dr. Ayman Moawad Mahmoud, Department of Life Sciences, Manchester Metropolitan University, Manchester, United Kingdom. E-mail:a.mahmoud@mmu.ac.uk

Summary

Although progress in anticancer therapy advancements was made somehow in the last decade, drug resistance of chemotherapy and immunotherapy with the subsequent spreading of metastases are the leading causes of failure in the treatment of multiple cancers. Drug resistance development involves dynamic changes of cancer heterogeneity as cancer evolves, as well as drug-induced physiological changes, specifically amplification/activation of oncogenes, loss/inactivation of tumor suppressor genes, dysregulation of transcriptional networks, altered metabolism, and microenvironment. Various clinical strategies, including combination therapies and epigenetic drugs, have been used to avoid or reverse drug resistance. Identifying both when the loss of efficacy in cancer drugs begins, and also the mechanism by which this resistance develops is of vital importance to clinicians and researchers tasked with identifying the issue, theorizing solutions, and implementing new treatments in the wake of resistance. The ultimate goal in these instances must be that of treating cancer and preventing further resistance development further down the line. By identifying these often unpredictable mechanisms of resistance, new refined drug molecules or drug delivery methods can be developed to avoid cancer drug resistance and ensure patient therapy is optimum. 

Keywords

Drug resistance; Cancer chemotherapy; cancer immunotherapy; Epigenetics

Published Papers

Show export options

  • Open Access

    ARTICLE

    Biological Features of KLC2 Mutations in Chronic Myeloid Leukemia and Their Contribution to Inducing Drug Resistance

    Rabindranath Bera, Yotaro Ochi, Ying-Jung Huang, Ming-Chung Kuo, Kenichi Yoshida, Seishi Ogawa, Lee-Yung Shih
    Oncology Research, DOI:10.32604/or.2025.070259
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Background: Breakpoint Cluster Region-Abelson (BCR::ABL1) fusion protein is essential in the pathogenesis of chronic myeloid leukemia (CML); however, the chronic-to-blast phase transformation remains elusive. We identified novel kinesin light chain 2 (KLC2) mutations in CML-myeloid blast phase patients. We aimed to examine the functional role of KLC2 mutations in leukemogenesis. Methods: To evaluate the biological role of KLC2 mutants (MT) in CML cells, we expressed KLC2-MT in different human CML cell lines harboring BCR::ABL1 and performed immunoblot, immunofluorescence, cell proliferation, differentiation, and apoptosis; Tyrosine kinase inhibitor (TKI)-drug activities; and clonogenic assays for in vitro functional analyses. We co-expressed KLC2-MT… More >

    View

    75

    Download

    19

  • Open Access

    REVIEW

    Research Progress of Drug Delivery Systems Consisting of Hydrogels Loaded with Extracellular Vesicles in Tumor Therapy

    Shaojian Zou, Lipeng Zhang, Xiang Chen, Zhuomin Wang, Xinhui Zhu, Dandong Luo, Shengxun Mao, Zhen Zong
    Oncology Research, Vol.33, No.12, pp. 3753-3788, 2025, DOI:10.32604/or.2025.067586
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Traditional cancer therapies have limitations like poor efficacy on advanced tumors, healthy tissue damage, side effects, and drug resistance, creating an urgent need for new strategies. Hydrogels have good biocompatibility and controlled release, while extracellular vesicles (EVs) enable targeting and bioactive transport. This review systematically summarizes hydrogels and EVs, focusing on the construction of hydrogel-EV delivery system, key influencing factors, drug delivery mechanisms, and tumor therapy apps, clarifying their synergies. The system overcomes single-carrier flaws, construction methods/key factors affect performance, preclinical studies have confirmed efficacy in multiple therapies, but large-scale production and in vivo stability challenges More >

    View

    266

    Download

    72

  • Open Access

    REVIEW

    Immune Checkpoint Inhibitors Combined with Oncolytic Virotherapy: Synergy, Heterogeneity, and Safety in Cancer Treatment

    Yi Feng, Haoxin Yang, Guicai Liang, Jun Chen, Tao Li, Yingjuan Wang, Jilin Chang, Yan Li, Meng Yang, Xilong Zhou, Zhiqiang Wang, Chunlei Ge
    Oncology Research, Vol.33, No.12, pp. 3801-3836, 2025, DOI:10.32604/or.2025.067824
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Immune checkpoint inhibitor (ICI) has limited efficacy in the treatment of immune “cold” tumors. Due to insufficient T cell infiltration and heterogeneous programmed death ligand 1 (PD-L1) expression, the ORR is only 5%–8% compared with 30%–40% of “hot” tumors. This article reviews the synergistic mechanism, clinical efficacy and optimization strategy of oncolytic virus (OVs) combined with ICIs in the treatment of refractory malignant tumors. Systematic analysis of mechanistic interactions across tumor types and clinical trial data demonstrates that OVs transform the immunosuppressive microenvironment by inducing immunogenic cell death and activating innate immunity. Concurrently, ICIs enhance… More >

    View

    815

    Download

    335

  • Open Access

    ARTICLE

    PFDN6L Gene Predicts Good Prognosis Associated with Its Inhibition of the Stem-Ness Properties in Hepatocellular Carcinoma

    Fangyuan Li, Xiaoyuan Hu, Xiaoge Gao, Ling Liu, Tao Li, Dan He, Jiaxing Cheng, Xiaobiao Ma, Li Li, Chunlei Ge, Hong Yao
    Oncology Research, Vol.33, No.12, pp. 4029-4048, 2025, DOI:10.32604/or.2025.067628
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Background: Liver cancer stem cells (LCSCs) are recognized as pivotal drivers of hepatocellular carcinoma (HCC) progression; however, the molecular mechanisms maintaining their stem-like phenotype remain largely unresolved. This work investigates the role of prefoldin subunit 6-like protein (PFDN6L) in shaping LCSC traits and promoting or restraining HCC progression. Methods: PFDN6L, a cytoskeleton-associated chaperone, was studied using multiple in vitro assays—cell growth evaluation, cell cycle profiling, and spheroid culture—alongside analyses of stemness-associated markers (SOX2, CD133, CD44). Tumorigenic capacity was assessed in xenograft mouse models, and signaling pathway interrogation was performed to define underlying mechanisms. Results: In patient samples, More >

    View

    422

    Download

    131

  • Open Access

    REVIEW

    Lactylation in Cancer: Unlocking the Key to Drug Resistance and Therapeutic Breakthroughs

    Xiangnan Feng, Dayong Li, Pingyu Wang, Xinyu Li, Guangyao Li
    Oncology Research, Vol.33, No.11, pp. 3327-3346, 2025, DOI:10.32604/or.2025.067343
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Lactylation, a post-translational modification process that adds lactate groups to lysine residues, plays a crucial role in cancer biology, especially in drug resistance. However, the specific molecular mechanisms of lactylation in cancer progression and drug resistance are still unclear, and therapeutic strategies targeting the lactylation pathway are expected to overcome metabolic reprogramming and immune evasion. Therefore, this article provides a comprehensive description and summary of lactylation modification and tumor drug resistance. Numerous studies have shown that, due to the Warburg effect, there is an abnormally high level of lactate in tumor cells. Elevated levels of… More >

    View

    1232

    Download

    325

  • Open Access

    ARTICLE

    A Machine-Learning Prognostic Model for Colorectal Cancer Using a Complement-Related Risk Signature

    Jun Li, Kangmin Yu, Zhiyong Chen, Dan Xing, Binshan Zha, Wentao Xie, Huan Ouyang, Changjun Yu
    Oncology Research, Vol.33, No.11, pp. 3469-3492, 2025, DOI:10.32604/or.2025.066193
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Objectives: Colorectal cancer (CRC) remains a major contributor to global cancer mortality, ranking second worldwide for cancer-related deaths in 2022, and is characterized by marked heterogeneity in prognosis and therapeutic response. We sought to construct a machine-learning prognostic model based on a complement-related risk signature (CRRS) and to situate this signature within the CRC immune microenvironment. Methods: Transcriptomic profiles with matched clinical annotations from TCGA and GEO CRC cohorts were analyzed. Prognostic CRRS genes were screened using Cox proportional hazards modeling alongside machine-learning procedures. A random survival forest (RSF) predictor was trained and externally validated.… More >

    View

    783

    Download

    181

  • Open Access

    REVIEW

    Exosomal Non-Coding RNAs in Pancreatic Cancer: From Mechanisms to Clinical Applications

    Chengru Yang, Zhiyu Wang, Shaowu Bi, Xinmiao Zhang, Zhaoqiang Xu, Yifei Ge, Tianjie Zhang, Nan Wang, Yi Xu, Xiangyu Zhong
    Oncology Research, Vol.33, No.11, pp. 3207-3229, 2025, DOI:10.32604/or.2025.066150
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Pancreatic cancer (PC) is an extremely aggressive cancer of the digestive system with insidious onset and the lack of effective biomarkers, resulting in late-stage diagnosis and poor prognosis. Exosomal non-coding RNAs (ncRNAs) are key mediators of intercellular communication that drive PC initiation and advancement. By modulating gene expression, they impact tumor microenvironment (TME) remodeling, proliferation, migration, apoptosis, and immune evasion. Critically, exosomal ncRNAs serve as promising biomarkers for early diagnosis and prognostic assessment. This review summarizes the current research achievements regarding exosomal ncRNAs in PC, systematically elaborating on their roles in tumor occurrence, metastasis, chemoresistance More >

    View

    786

    Download

    207

  • Open Access

    ARTICLE

    Discovery and Characterization of Novel IKZF1/3 Glue Degraders against Multiple Hematological Cancer Cell Lines

    Ting Wei, Pengli Wei, Yalei Wang, Yaqiu Mao, Jian Yan, Xiaotong Hu, Zhenze Qi, Xu Cai, Changkai Jia, Zhiyuan Zhao, Bingkun Li, Min Qiao, Yaxin Zou, Tingting Yang, Shiyang Sun, Xuesong Feng, Pengyun Li, Hongzhou Shang, Zhibing Zheng
    Oncology Research, Vol.33, No.10, pp. 2981-3006, 2025, DOI:10.32604/or.2025.065123
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Objectives: Immunomodulatory drugs (IMiDs), functioning as molecular glue degraders, have been approved for treating various hematological malignancies; however, the inevitable acquired drug resistance resulting from their skeletal similarity and hematological toxicities poses significant obstacles to their clinical treatment. The study aimed to develop degraders with potent efficiency and low toxicity. Methods: Phenotypic profiling, elaborate structure-activity relationships (SAR), rational drug design and degradation profiles investigations, quantitative proteomics analysis and cell-based functional studies, and pharmacokinetic studies were conducted to develop more potent degraders. Results: This study developed novel CRBN-binding moieties through methylene deletion in lenalidomide’s isoindole core. Lead… More >

    Graphic Abstract

    Discovery and Characterization of Novel IKZF1/3 Glue Degraders against Multiple Hematological Cancer Cell Lines

    View

    1653

    Download

    629

  • Open Access

    ARTICLE

    SORBS1 Knockdown Resists S/G2 Arrest and Apoptosis Caused by Polyphyllin H-Induced DNA Damage in Pancreatic Cancer

    Xinxin Hu, Yuye Xue, Fei Fang, Jie Li, Xiaofeng Yuan, Guang Cheng, Hailong Yuan, Yongqiang Zhang, Yuefei Zhou, Shuangwu Yang, Pengcheng Qiu, Yunyang Lu, Haifeng Tang
    Oncology Research, Vol.33, No.9, pp. 2491-2506, 2025, DOI:10.32604/or.2025.064454
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Objectives: The Sorbin and SH3 domain containing 1 (SORBS1), a protein linked to insulin signaling CBL interaction, was investigated for its role in pancreatic cancer apoptosis. This study explored polyphyllin H (PPH)’s ability to restore SORBS1-knockdown-mediated repair functions. Methods: PANC-1 cells were divided into Blank, overexpression (OE), and knockdown groups. CCK-8 assays assessed proliferation and drug toxicity. Western blot and flow cytometry analyzed SORBS1 levels and PPH effects. Comet assays quantified DNA damage. Subcutaneous xenograft tumors in nude mice (Blank vs. knockdown) were treated with PPH to evaluate in vivo efficacy. SORBS1-H2AX gene correlation was analyzed… More >

    Graphic Abstract

    SORBS1 Knockdown Resists S/G2 Arrest and Apoptosis Caused by Polyphyllin H-Induced DNA Damage in Pancreatic Cancer

    View

    1679

    Download

    1051

  • Open Access

    REVIEW

    Tumor Vaccines for Malignant Melanoma: Progress, Challenges, and Future Directions

    Wenfei Luo, Dingming Song, Yibo He, Judong Song, Yunzhen Ding
    Oncology Research, Vol.33, No.8, pp. 1875-1893, 2025, DOI:10.32604/or.2025.063843
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Malignant melanoma, characterized by its high metastatic potential and resistance to conventional therapies, presents a major challenge in oncology. This review explores the current status and advancements in tumor vaccines for melanoma, focusing on peptide, DNA/RNA, dendritic cell, tumor cell, and neoantigen-based vaccines. Despite promising results, significant challenges remain, including the immunosuppressive tumor microenvironment, patient heterogeneity, and the need for more effective antigen presentation. Recent strategies, such as combining vaccines with immune checkpoint inhibitors (ICIs), aim to counteract immune evasion and enhance T cell responses. Emerging approaches, including personalized neoantigen vaccines and the use of More >

    Graphic Abstract

    Tumor Vaccines for Malignant Melanoma: Progress, Challenges, and Future Directions

    View

    2273

    Download

    1044

  • Open Access

    REVIEW

    Plasticity of myeloid-derived suppressor cells in cancer and cancer therapy

    JIAJIA LV, XIAOYOU ZHONG, LIN WANG, WEIFEI FAN
    Oncology Research, Vol.33, No.7, pp. 1581-1592, 2025, DOI:10.32604/or.2025.060063
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract The tumor microenvironment (TME) is a complex and dynamic network comprised of tumor cells, surrounding cellular components, various signaling molecules, and the stroma. Myeloid-derived suppressor cells (MDSCs) are pivotal players in the immunosuppressive landscape of the TME, effectively hindering antitumor immune responses and facilitating tumor progression. Originating from pathologically activated myeloid precursors and relatively immature myeloid cells, MDSCs retain plasticity to further differentiate into other myeloid cells, such as macrophages or dendritic cells, which underpins their heterogeneity and adaptability in response to the TME. In this review, we delve into the plasticity of MDSCs in More >

    View

    1272

    Download

    598

  • Open Access

    REVIEW

    The regulatory role of lncRNA in tumor drug resistance: refracting light through a narrow aperture

    HENG ZHANG, XIAO YANG, YUJIN GUO, HAIBO ZHAO, PEI JIANG, QING-QING YU
    Oncology Research, Vol.33, No.4, pp. 837-849, 2025, DOI:10.32604/or.2024.053882
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract As living conditions improve and diagnostic capabilities advance, the incidence of tumors has increased, with cancer becoming a leading cause of death worldwide. Surgery, chemotherapy, and radiotherapy are the most common treatments. Despite advances in treatment options, chemotherapy remains a routine first-line treatment for most tumors. Due to the continuous and extensive use of chemotherapy drugs, tumor resistance often develops, becoming a significant cause of treatment failure and poor prognosis. Recent research has increasingly focused on how long stranded non-coding RNAs (LncRNAs) influence the development of malignant tumors and drug resistance by regulating gene expression More >

    View

    1809

    Download

    1042

  • Open Access

    REVIEW

    Oncogenic and tumor-suppressive roles of Lipocalin 2 (LCN2) in tumor progression

    BAOXING HUANG, ZICHANG JIA, CHENCHEN FU, MOXIAN CHEN, ZEZHUO SU, YUNSHENG CHEN
    Oncology Research, Vol.33, No.3, pp. 567-575, 2025, DOI:10.32604/or.2024.051672
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Lipocalin-2 (LCN2) is a member of the lipocalin superfamily with multiple functions and can participate in the transport of a variety of small lipophilic ligands in vivo. LCN2 is significantly expressed in various tumors and plays an important role in regulating tumor cell proliferation, invasion, and metastasis. The specific actions of LCN2 in tumors may vary depending on the particular type of cancer involved. In this review, we provide an extensive overview of the transcriptional and post-transcriptional regulation of LCN2 in health and disease. Furthermore, we summarize the impact of LCN2 dysregulation in a broad range More >

    View

    2265

    Download

    1115

  • Open Access

    ARTICLE

    Ultrasound genomics related mitochondrial gene signature for prognosis and neoadjuvant chemotherapy resistance in triple negative breast cancer

    HUAFANG HUANG, GUILIN WANG, DONGYUN ZENG, LUZ ANGELA TORRES-DE LA ROCHE, RUI ZHUO, RUDY LEON DE WILDE, WANWAN WANG, ULF D. KAHLERT, WENJIE SHI
    Oncology Research, Vol.33, No.3, pp. 631-640, 2025, DOI:10.32604/or.2024.054642
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Background: Neoadjuvant chemotherapy (NAC) significantly enhances clinical outcomes in patients with triple-negative breast cancer (TNBC); however, chemoresistance frequently results in treatment failure. Consequently, understanding the mechanisms underlying resistance and accurately predicting this phenomenon are crucial for improving treatment efficacy. Methods: Ultrasound images from 62 patients, taken before and after neoadjuvant therapy, were collected. Mitochondrial-related genes were extracted from a public database. Ultrasound features associated with NAC resistance were identified and correlated with significant mitochondrial-related genes. Subsequently, a prognostic model was developed and evaluated using the GSE58812 dataset. We also assessed this model alongside clinical factors… More >

    View

    2074

    Download

    1383

  • Open Access

    ARTICLE

    Astragalus polysaccharide enhances the therapeutic efficacy of cisplatin in triple-negative breast cancer through multiple mechanisms

    LI SUN, SHICHAO ZHUO, XIAOXIN LI, HUSHENG KONG, WEIWEI DU, CHONG ZHOU, JUNXING HUANG
    Oncology Research, Vol.33, No.3, pp. 641-651, 2025, DOI:10.32604/or.2024.050057
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Background: Cisplatin (DDP) has been used in the treatment of various human cancers. However, DDP alone lacks efficacy in treating triple-negative breast cancer (TNBC), and its clinical application is often hampered by side effects. Astragalus polysaccharide (APS) is one of the active components extracted from Astragalus membranaceus and has gained attention for its various biological properties. This research is aimed to evaluate the effectiveness of a combination of APS and DDP on TNBC and explore the potential mechanisms. Methods: The efficacy and mechanisms of single or combined treatment were evaluated using Cell Counting Kit-8 (CCK8) assay, Annexin… More >

    View

    2649

    Download

    1570

  • Open Access

    ARTICLE

    Loss of TNFRSF21 induces cisplatin sensitivity in lung adenocarcinoma

    DAIEN ZHOU, HAOYANG YUAN, YIWEI HU, CHUXU WANG, SA GE, KOUFENG SHAO, HONGYING WANG, XIAOFENG TIAN, HAIBO HU
    Oncology Research, Vol.33, No.3, pp. 653-663, 2025, DOI:10.32604/or.2024.050182
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Background: Despite the identification of numerous therapeutic targets in lung cancer, achieving significant efficacy has been challenging. TNFRSF21 plays an important role in various cancers. We investigated the function of TNFRSF21 in lung adenocarcinoma (LUAD). Methods: The prognostic value of TNFRSF21 expression in lung cancer was evaluated by the GEPIA and Kaplan-Meier Plotter databases. Lung cancer cell viability was assessed by the CCK8 assay. TNFRSF21 expression patterns in lung cancer tissues and cells were examined using RT-PCR assay. Tumor sphere growth was evaluated through tumor sphere formation assays. MtROS contents in lung cancer cells were… More >

    View

    1917

    Download

    1018

  • Open Access

    ARTICLE

    Genetic signatures of ERCC1 and ERCC2 expression, along with SNPs variants, unveil favorable prognosis in SCLC patients undergoing platinum-based chemotherapy

    ENRICO CALIMAN, SARA FANCELLI, FEDERICO SCOLARI, ADRIANO PASQUI, CLARA MANNESCHI, DANIELE LAVACCHI, FRANCESCA MAZZONI, FRANCESCA GENSINI, VALERIA PASINI, CAMILLA EVA COMIN, LUCA VOLTOLINI, SERENA PILLOZZI, LORENZO ANTONUZZO
    Oncology Research, Vol.33, No.1, pp. 45-55, 2025, DOI:10.32604/or.2024.050161
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Background: Platinum chemotherapy (CT) remains the backbone of systemic therapy for patients with small-cell lung cancer (SCLC). The nucleotide excision repair (NER) pathway plays a central role in the repair of the DNA damage exerted by platinum agents. Alteration in this repair mechanism may affect patients’ survival. Materials and Methods: We conducted a retrospective analysis of data from 38 patients with extensive disease (ED)-SCLC who underwent platinum-CT at the Clinical Oncology Unit, Careggi University Hospital, Florence (Italy), from 2015 to 2020. mRNA expression analysis and single nucleotide polymorphism (SNP) characterization of three NER pathway genes—namely ERCC1, ERCC2,… More >

    View

    2683

    Download

    976

  • Open Access

    ARTICLE

    The superiority of PMFs on reversing drug resistance of colon cancer and the effect on aerobic glycolysis-ROS-autophagy signaling axis

    YUQIN YIN, YU WU, HONGLIANG HUANG, YINGYING DUAN, ZHONGWEN YUAN, LIHUI CAO, JINJIN YING, YONGHENG ZHOU, SENLING FENG
    Oncology Research, Vol.32, No.12, pp. 1891-1902, 2024, DOI:10.32604/or.2024.048778
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Background: Polymethoxylated flavones (PMFs) are compounds present in citrus peels and other Rutaceae plants, which exhibit diverse biological activities, including robust antitumor and antioxidant effects. However, the mechanism of PMFs in reversing drug resistance to colon cancer remains unknown. In the present study, we aimed to investigate the potential connection between the aerobic glycolysis-ROS-autophagy signaling axis and the reversal of PTX resistance in colon cancer by PMFs. Methods: MTT Cell viability assay and colony formation assay were used to investigate the effect of PMFs combined with PTX in reversing HCT8/T cell resistance ex vivo; the mRNA… More >

    Graphic Abstract

    The superiority of PMFs on reversing drug resistance of colon cancer and the effect on aerobic glycolysis-ROS-autophagy signaling axis

    View

    3354

    Download

    1217

  • Open Access

    ARTICLE

    Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation

    ZHILI ZHUO, DONGNI ZHANG, WENPING LU, XIAOQING WU, YONGJIA CUI, WEIXUAN ZHANG, MENGFAN ZHANG
    Oncology Research, Vol.32, No.6, pp. 1093-1107, 2024, DOI:10.32604/or.2024.047257
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Breast cancer is the leading cause of cancer-related deaths in women worldwide, with Hormone Receptor (HR)+ being the predominant subtype. Tamoxifen (TAM) serves as the primary treatment for HR+ breast cancer. However, drug resistance often leads to recurrence, underscoring the need to develop new therapies to enhance patient quality of life and reduce recurrence rates. Artemisinin (ART) has demonstrated efficacy in inhibiting the growth of drug-resistant cells, positioning art as a viable option for counteracting endocrine resistance. This study explored the interaction between artemisinin and tamoxifen through a combined approach of bioinformatics analysis and experimental… More >

    Graphic Abstract

    Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation

    View

    2600

    Download

    1179

  • Open Access

    ARTICLE

    A comparative in vitro study on the effect of SGLT2 inhibitors on chemosensitivity to doxorubicin in MCF-7 breast cancer cells

    SHAHID KARIM, ALANOUD NAHER ALGHANMI, MAHA JAMAL, HUDA ALKREATHY, ALAM JAMAL, HIND A. ALKHATABI, MOHAMMED BAZUHAIR, AFTAB AHMAD
    Oncology Research, Vol.32, No.5, pp. 817-830, 2024, DOI:10.32604/or.2024.048988
    （This article belongs to the Special Issue: New Insights in Drug Resistance of Cancer Therapy: A New Wine in an Old Bottle)
    Abstract Cancer frequently develops resistance to the majority of chemotherapy treatments. This study aimed to examine the synergistic cytotoxic and antitumor effects of SGLT2 inhibitors, specifically Canagliflozin (CAN), Dapagliflozin (DAP), Empagliflozin (EMP), and Doxorubicin (DOX), using in vitro experimentation. The precise combination of CAN+DOX has been found to greatly enhance the cytotoxic effects of doxorubicin (DOX) in MCF-7 cells. Interestingly, it was shown that cancer cells exhibit an increased demand for glucose and ATP in order to support their growth. Notably, when these medications were combined with DOX, there was a considerable inhibition of glucose consumption, as More >

    Graphic Abstract

    A comparative <i>in vitro</i> study on the effect of SGLT2 inhibitors on chemosensitivity to doxorubicin in MCF-7 breast cancer cells

    View

    3357

    Download

    1241

Copyright© 2025 Tech Science Press
© 1997-2025 TSP (Henderson, USA) unless otherwise stated

Share Link